Gainor B J, Forbes J T, Enneking W F, Smith R T
Cancer. 1976 Feb;37(2):743-50. doi: 10.1002/1097-0142(197602)37:2<743::aid-cncr2820370222>3.0.co;2-0.
A lymphocyte proliferation assay (LPA) for cellular immune responses to osteosarcoma antigens is described and applied to an examination of peripheral blood lymphocytes (PBL) taken from osteosarcoma patients. The antigen preparations were derived from 3 M KC1 solubilized osteosarcoma, taken from a limited number of patients. Lymphocytes from most tumor-bearing patients were stimulated to significant proliferation when cultured in normal human serum. Such stimulation was observed whether or not the lymphoid cells were preincubated 24 hours at 37 degrees C prior to addition of antigen. Patients whose lesion had been resected and who were without evidence of disease for 5-70 months had diminished proliferative responses. Lymphocytes from normal subjects, from patients having other types of sarcoma, and patients having carcinomas rarely responded to the soluble osteosarcoma antigens. When responsive PBL taken from tumor-bearing patients were cultured in autologous serum, the proliferative responses were abrogated or blocked. Serial assays made in the course of bearing this tumor under a variety of therapeutic regimens, including an immunotherapy protocol, suggest that the LPA may be useful in monitoring clinical progress of the disease and possibly in other immunotherapy protocols for osteosarcoma.
本文描述了一种用于检测对骨肉瘤抗原的细胞免疫反应的淋巴细胞增殖试验（LPA），并将其应用于对骨肉瘤患者外周血淋巴细胞（PBL）的检测。抗原制剂来自于用3M氯化钾溶解的骨肉瘤，取材于少数患者。大多数荷瘤患者的淋巴细胞在正常人血清中培养时会被刺激发生显著增殖。无论淋巴细胞在添加抗原之前是否在37℃预孵育24小时，均观察到这种刺激现象。病变已切除且无疾病证据达5至70个月的患者，其增殖反应减弱。来自正常受试者、患有其他类型肉瘤的患者以及患有癌症的患者的淋巴细胞很少对可溶性骨肉瘤抗原产生反应。当将取自荷瘤患者的反应性PBL在自体血清中培养时，增殖反应被消除或阻断。在多种治疗方案（包括免疫治疗方案）下对患有该肿瘤的患者进行的系列检测表明，LPA可能有助于监测疾病的临床进展，并且可能在骨肉瘤的其他免疫治疗方案中也有用。
